Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hough

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
CNS Spectrums|August 13, 2010
One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophreniaMichelle Kramer, George Simpson, Valentinas Maciulis, et al.
Journal of Clinical Psychopharmacology|February 21, 2013
Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trialsSrihari Gopal, David Hough, Keith Karcher, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 18, 2010
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaHenry A Nasrallah, Srihari Gopal, Cristiana Gassmann-Mayer, et al.
The International Journal of Neuropsychopharmacology|February 24, 2016
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority StudyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Journal of Clinical Pharmacology|July 21, 2015
Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label studyPaulien Ravenstijn, Bart Remmerie, Adam Savitz, et al.
Nucleic Acids Research|August 15, 2008
The structure of SgrAI bound to DNA; recognition of an 8 base pair targetPete W Dunten, Elizabeth J Little, Mark T Gregory, et al.
AJR. American Journal of Roentgenology|December 17, 2005
Colonic perforation at CT colonography in a patient without known colonic diseaseBrett M Young, Joel G Fletcher, Frank Earnest, et al.
Current Medical Research and Opinion|August 27, 2015
Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophreniaSrihari Gopal, An Vermeulen, Partha Nandy, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophreniaStefaan Rossenu, Adriaan Cleton, David Hough, et al.
The Journal of Clinical Psychiatry|May 16, 2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)Dong-Jing Fu, Dawn F Ionescu, Xiang Li, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
CNS Spectrums|August 13, 2010
One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophreniaMichelle Kramer, George Simpson, Valentinas Maciulis, et al.
Journal of Clinical Psychopharmacology|February 21, 2013
Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trialsSrihari Gopal, David Hough, Keith Karcher, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 18, 2010
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaHenry A Nasrallah, Srihari Gopal, Cristiana Gassmann-Mayer, et al.
The International Journal of Neuropsychopharmacology|February 24, 2016
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority StudyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Journal of Clinical Pharmacology|July 21, 2015
Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label studyPaulien Ravenstijn, Bart Remmerie, Adam Savitz, et al.
Nucleic Acids Research|August 15, 2008
The structure of SgrAI bound to DNA; recognition of an 8 base pair targetPete W Dunten, Elizabeth J Little, Mark T Gregory, et al.
AJR. American Journal of Roentgenology|December 17, 2005
Colonic perforation at CT colonography in a patient without known colonic diseaseBrett M Young, Joel G Fletcher, Frank Earnest, et al.
Current Medical Research and Opinion|August 27, 2015
Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophreniaSrihari Gopal, An Vermeulen, Partha Nandy, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophreniaStefaan Rossenu, Adriaan Cleton, David Hough, et al.
The Journal of Clinical Psychiatry|May 16, 2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)Dong-Jing Fu, Dawn F Ionescu, Xiang Li, et al.
Pageof 7